The Biotech Bi-Weekly: Cell-Free Synthesis, in Situ Hybridization and Antibody Conjugation

Key Takeaways

• Ribbon Bio launches MiroSynth cell‑free DNA platform, eliminating cloning steps
• Empire Genomics and Molecular Instruments debut NISH, largest automated RNA‑ISH library
• Bio‑Rad expands TrailBlazer StarBright kits, now fully available in Europe
• Isomorphic Labs raises $2.1 B Series B to scale AI drug‑design engine
• 10x Genomics Q1 revenue $150.8 M; Atera launch fuels spatial biology growth

Pulse Analysis

Ribbon Bio’s MiroSynth and accompanying MiroMine kit represent a shift toward cell‑free synthetic DNA production, removing traditional cloning bottlenecks. By delivering high‑fidelity DNA directly from enzymatic assembly, researchers can shorten design‑to‑experiment cycles, lower reagent costs, and broaden access to custom gene constructs for CRISPR, vaccine, and gene‑therapy projects. This democratization aligns with the growing demand for rapid prototyping in synthetic biology and could spur new collaborations between academic labs and biotech startups.

Automation is also redefining molecular diagnostics. Empire Genomics and Molecular Instruments’ NISH library, built on HCR™ Pro technology, offers a fully automated, ready‑to‑use solution for RNA in situ hybridization on formalin‑fixed tissues, enabling high‑throughput spatial transcriptomics without manual probe preparation. Coupled with Bio‑Rad’s expanded TrailBlazer StarBright dye‑label kits—now stocked across Europe—researchers gain streamlined workflows for multiplexed flow cytometry and fluorescent western blots. Meanwhile, Action for ME’s partnership with Oxford Nanopore, the University of Edinburgh, and EMBL‑EBI aims to generate the first comprehensive genomic dataset for chronic‑fatigue‑syndrome and Long COVID, underscoring how advanced sequencing can illuminate complex, poorly understood diseases.

Capital inflows signal confidence in AI‑augmented drug discovery. Isomorphic Labs secured $2.1 billion in Series B funding to scale its AI engine, accelerating the transition from model development to clinical candidate generation. The parallel collaboration between Suzhou Ribo Life Science and Insilico Medicine merges siRNA expertise with AI‑driven target identification, promising faster routes to novel therapeutics. Financially, 10x Genomics posted $150.8 million in Q1 revenue, a modest dip year‑over‑year but offset by strong growth in spatial biology consumables, especially after the launch of the Atera platform. Together, these trends illustrate a biotech landscape increasingly powered by automation, AI, and strategic financing, driving faster innovation cycles and broader market adoption.